533.50
0.44%
Deven Choksey
The near-term headwinds—muted domestic demand, elevated employee costs, and gestation-led pressure from new capacities—are likely to keep earnings growth and return ratios subdued over the next few quarters.
Deven Choksey decreased Buy price target of Rossari Biotech Ltd. to 637.0 on 21 Jan, 2026.
More from Rossari Biotech Ltd.
Recommended